Guggenheim maintains a “Buy” rating for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) despite challenges, including the delayed regulatory submissions of Itepekimab. The delay in Itepekimab’s approval ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Sanofi (SNY) stock and Regeneron (REGN) stock fell after the companies reported mixed Phase 3 results for their COPD therapy ...

(Reuters) -Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition ...

Sanofi and Regeneron said that drug candidate Itepekimab didn’t meet primary endpoint in a phase three study, although a ...

Regeneron shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of lung ...

To help address the impact of COPD on patients and communities, global healthcare companies Sanofi and Regeneron are working together to study the ripple effects of COPD and to help create a ...

Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Adam Kovalcík, 19, of Dulovce, Slovakia, won the $100,000 George D. Yancopoulos Innovator Award at the 75 th ...

TARRYTOWN, N.Y. and WASHINGTON, May 16, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Adam Kovalčík, 19 ...

Regeneron Pharmaceuticals (REGN) reported its first-quarter 2025 earnings, revealing a miss on both earnings and revenue expectations. The company posted earnings per share (EPS) of $8.22, falling ...